Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Core Scientific (CORZ) EBITDA Margin (2021 - 2025)

Core Scientific's EBITDA Margin history spans 5 years, with the latest figure at 149.55% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 2180.0% year-over-year to 149.55%; the TTM value through Dec 2025 reached 76.16%, down 2929.0%, while the annual FY2025 figure was 76.98%, 4916.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 149.55% at Core Scientific, down from 67.56% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 33.85% in Q4 2021 and bottomed at 637.54% in Q2 2022.
  • The 5-year median for EBITDA Margin is 23.65% (2025), against an average of 96.14%.
  • The largest annual shift saw EBITDA Margin tumbled -63560bps in 2022 before it soared 64493bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 33.85% in 2021, then tumbled by -1650bps to 524.6% in 2022, then surged by 101bps to 2.83% in 2023, then tumbled by -6151bps to 171.35% in 2024, then rose by 13bps to 149.55% in 2025.
  • Per Business Quant, the three most recent readings for CORZ's EBITDA Margin are 149.55% (Q4 2025), 67.56% (Q3 2025), and 33.43% (Q2 2025).